---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-000089"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2025-01-07T23:59:59+00:00"
generated_at: "2026-05-28T07:43:14.946116+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cassava cuts workforce 33% after Phase 3 miss; REFOCUS-ALZ results due Q1/Q2 2025

## Summary
- Workforce reduction of 10 employees (33%) with ~$0.4M severance costs in Q1 2025.
- Cash and cash equivalents ~$128.6M as of Dec 31, 2024 (unaudited).
- Topline data from Phase 3 REFOCUS-ALZ study expected late Q1/early Q2 2025.
- Halting planned biomarker analysis of additional plasma samples from prior Phase 2 studies.
- RETHINK-ALZ study did not meet co-primary endpoints; REFOCUS-ALZ and OLE study discontinued.

## SEC filing metadata
- accession: 0001171843-25-000089
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2025-01-07T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000117184325000089/0001171843-25-000089-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000117184325000089/f8k_010725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-000089
- JSON: https://secwatch.observer/filing/0001171843-25-000089.json
- Plain text: https://secwatch.observer/filing/0001171843-25-000089.txt

## Key facts
- Restructurings & Charges
  FILANA THERAPEUTICS, INC. announced a restructuring with charges of approximately $0.4 million (10 employees, a reduction of 33%).
  - Type: restructuring
  - Charge: approximately $0.4 million
  - Headcount: 10 employees, a reduction of 33%
  source text: The Company estimates that it will incur approximately $0.4 million of one-time costs in connection with the Workforce Reduction, primarily related to severance payments.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1069530/000117184325000089/0001171843-25-000089-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.